Back to search results

A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Colorectal Cancer · Pancreatic Cancer · Non-Small Cell Lung Cancer · Solid Tumor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Dana-Farber/Massachusetts General Hospital, Inc, Boston, Massachusetts, United States

    Contact: Study coordinator (Leon Pappas) · lpappas3@mgb.org

  • New Experimental Therapeutics of San Antonio LLC, San Antonio, Texas, United States

    Contact: Study coordinator (Ildefonso Ismael Rodriguez Rivera) · irodriguez@nextoncology.com

  • START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States

    Contact: Study coordinator (Drew Rasco) · drasco@startsa.com

  • START Mountain Region, West Valley City, Utah, United States

    Contact: Study coordinator (William McKean) · william.mckean@startresearch.com

  • NEXT Virginia, Fairfax, Virginia, United States

    Contact: Study coordinator (Alexander Spira) · aspira@nextoncology.com

  • Samsung Medical Center, Seoul, South Korea

    Contact: Study coordinator (JoonOh Park)

  • Seoul National University Bundang Hospital, Seoul, South Korea

    Contact: Study coordinator (Jinwon kim)

  • Seoul National University Hospital, Seoul, South Korea

    Contact: Study coordinator (Do-Youn Oh)

  • Severance Hospital, Yonsei University Health System, Seoul, South Korea

    Contact: Study coordinator (HyeJin Choi)
View source on ClinicalTrials.gov(opens in a new tab)